Telix Medical

Interested to understand more about small molecule- and antibody-based approaches in radiopharmaceuticals? Join 5 internationally renowned key opinion leaders at Telix’s symposium at EANM, ‘Does size matter in targeted radionuclide therapies?’ Speakers will share their perspectives on the pros and cons of different targeting agents in uro-oncology, neuro-oncology, and onco-hematology. Details of the symposium can be found on our website here: https://lnkd.in/gsEB6NTd #EANM2024

Illuccix® (kit for the preparation of 68Ga-PSMA-11 injection*) is now registered in Australia for selection of patients with metastatic prostate cancer in whom lutetium Lu 177 vipivotide tetraxetan PSMA-directed therapy is indicated. Professor Andrew Scott AM, Director of the Department of Molecular Imaging and Therapy at Austin Health, explains how label expansion may help with clinical decision making and improve patient outcomes. Read more on our website: https://bit.ly/3ZVKbQz *also known as Ga-68 Glu-urea-Lys(ahx)-hbed-CC.

Telix is pleased to support the 2024 Australia and New Zealand Sarcoma Association Annual Scientific Meeting taking place today and tomorrow in Brisbane, Australia. Drop in and meet our team to learn more about TLX300, Telix’s theranostic program for sarcoma, and the soon to commence ZOLAR study, an open-label, Phase I study of pharmacokinetics and imaging properties of 89Zr-olaratumab (TLX300-CDx) in soft tissue sarcoma. To learn more about the event, visit the conference website here: https://lnkd.in/gwEcqi2f ISOLS International Society of Limb Salvage

Telix MD and Group CEO Chris Behrenbruch sat down with Dr Oliver Sartor from Mayo Clinic recently for a wide-ranging interview on nuclear medicine and the potential for patient impact. They explore the complexities of isotope selection and the importance of matching isotopes to tumour biology, the potential of alpha emitters, and the importance of developing new targets and biomarkers. Chris describes the role of both small molecules and biologics in radiopharmaceuticals, and the potential for combinations with immunotherapy in cancer treatment. He gives his prediction for what the space might look like in five years time, and what we will know then that we don’t know today. Listen to the full interview here: https://bit.ly/3THuYyx

Telix is attending the 2nd Annual Targeted Radiopharmaceuticals Supply Chain and Manufacturing Summit, taking place next week in Boston, MA. The event is a key industry driven forum dedicated to advancing radiopharmaceutical supply production. Telix’s Senior Director Global Supply Chain, Brett Miller, will Chair the event, and with SVP Global Manufacturing Operations, Michelle Hickey, will present and facilitate a roundtable on the development of radiopharmaceutical production facilities. To view the full event guide and to register, visit: https://lnkd.in/gsrXiJiU

Telix’s Phase III ZIRCON trial of TLX250-CDx ([⁸⁹Zr]girentuximab) has been published in The Lancet Oncology In this first peer-reviewed manuscript, Prof. Brian Shuch and colleagues report that “[⁸⁹Zr]girentuximab PET–CT is a highly accurate, non-invasive imaging modality for the detection and characterisation of clear-cell renal cell carcinoma (ccRCC)”. For detection of ccRCC in patients with an indeterminate renal mass (IRM) ≤7 cm, authors report that [⁸⁹Zr]girentuximab PET–CT had a mean sensitivity and specificity of 86% and 87%, respectively, and positive predictive value of 93%. Diagnostic performance was consistent in patients irrespective of smaller size IRMs (≤4 cm, ≤3 cm, and ≤2 cm). Authors conclude that “PET–CT imaging accurately identified ccRCC in patients with cT1 indeterminate renal masses (≤7 cm), with a favourable safety profile. These results establish the value of [⁸⁹Zr]girentuximab PET–CT imaging as a new standard, non-invasive tool for the diagnosis and detection, characterisation and differentiation of ccRCC from other renal and extrarenal lesions in clinical practice, minimising the risk of unnecessary invasive interventions.” To read more, including the full article, visit our website here: https://lnkd.in/g8hVCsNN

Telix is pleased to attend the Chinese Society of Nuclear Medicine (CSNM) annual meeting taking place this week in Zhengzhou, China. The program features a “Project Highlight” oral presentation on the ZIRDOSE-CP study of Zircaix® (TLX250-CDx), in Chinese patients with indeterminate renal masses. The study has completed enrolment and precedes the multi-centre Phase III ZIRCON-CHINA registration study, which is intended to bridge to Telix’s global Phase III ZIRCON trial. To learn more about the event, visit the conference website here: https://lnkd.in/gJ-JXb4s

Results published in Neuro-Oncology Advances from Telix’s Phase I IPAX-1 study demonstrate the therapeutic potential of TLX101 (4-L-[131I]iodo-phenylalanine ([131I]IPA) plus external beam radiation therapy for patients with recurrent glioblastoma. Pichler et al. report that 44% of patients had stable disease at 3-months post-treatment, with median overall survival (OS) 23 months from initial diagnosis, compared with 12-15 months median OS in the absence of treatment. Authors also report a favourable safety and tolerability profile. Findings support further evaluation in the recurrent setting, and also as a front-line therapy where TLX101 is currently being investigated in the IPAX-Linz and IPAX-2 studies. The full paper is available online at: https://lnkd.in/eutzaFP4 TLX101 has not received a marketing authorisation in any jurisdiction.

Telix is pleased to support the 2024 American Brain Tumor Association (ABTA) National Conference taking place this week in Chicago, IL and online. The largest conference of its kind in the United States is designed specifically for patients, caregivers, and survivors to understand more about the latest advances in brain tumor treatment and care from internationally recognized experts. For more information and to register visit: https://lnkd.in/euTXQj33

Internationally recognised medical oncologist, Prof. Scott Tagawa, MD, visited our Melbourne HQ today to meet the team and share his perspectives on targeted radionuclide therapy and the treatment of prostate cancer. It's always insightful to hear from the medical professionals at the forefront of cancer research and a valuable opportunity to thank him for his ongoing collaboration. Prof. Tagawa is in Melbourne this week to present at the 24th Asia Pacific Prostate Cancer Conference, including at four Telix-sponsored sessions where he will delve into the latest advances in prostate cancer theranostics. To view the full APCC schedule visit their website here: https://lnkd.in/gWe_wnU8